Statistical analysis of differences in the Raman spectra of polymorphs

Journal of Pharmaceutical Sciences

Volumn 94, Issue 6, 2005, Pages 1354-1367

  Mehrens, Shawn M ^a   Kale, Uma J ^a   Qu, Xianggui ^b  

^a PFIZER INC   (United States)

^b OAKLAND UNIVERSITY   (United States)

Author keywords

Polymorphs; Raman spectroscopy; Statistical analysis

Indexed keywords

CHLORPROPAMIDE; DIFLUNISAL; FUROSEMIDE; PIROXICAM; RITONAVIR;

ANALYSIS OF VARIANCE; ARTICLE; CALCULATION; DRUG PACKAGING; INTERMETHOD COMPARISON; MICROSCOPY; RAMAN SPECTROMETRY; SPECTROSCOPY; STATISTICAL ANALYSIS;

EID: 21344473636     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.20355     Document Type: Article

References (17)

1. Haleblian J, McCrone W. 1969. Pharmaceutical applications of polymorphism. J Pharm Sci 58:911-929.
2. Haleblian J. 1975. Characterization of habits and crystalline modification of solids and their pharmaceutical applications. J Pharm Sci 64:1269-1288.
3. Peterson ML, Morissette SL, McNulty C, Goldsweig A, Shaw P, LeQuesne M, Monagle J, Encina N, Marchionna J, Johnson A, Gonzalez-Zugasti J, Lemmo AV, Ellis SJ, Cima MJ, Almarsson Ö. 2002. Iterative high-throughput polymorphism studies on acetaminophen and an experimentally derived structure for form III: Communication. J Am Chem Soc 124:10958-10959.
4. Chemburkar SR, Bauer J, Deming K, Spiwek H, Patel K, Morris J, Henry R, Spanton S, Dziki W, Porter W, Quick J, Bauer P, Donaubauer J, Narayanan BA, Soldani M, Riley D, McFarland K. 2000. Dealing with the impact of ritonavir polymorphs on the late stages of bulk drug process development. Org Process Res Dev 4:413-417.
5. Findlay WP, Bugay DE. 1998. Utilization of Fourier transform-Raman spectroscopy for the study of pharmaceutical crystal forms. J Pharm Biomed Anal 16:921-930.
6. Fini G. 2004. Applications of Raman spectroscopy to pharmacy. J Raman Spectrosc 35:335-337.
7. Pînzaru SC, Pavel I, Leopold N, Kiefer W. 2004. Identification and characterization of pharmaceuticals using Raman and surface enhanced Raman spectroscopy. J Raman Spectrosc 35:338-346.
8. Morrissette S, Soukasene S, Levinson D, Sima MJ, Almarsson Ö. 2003. Elucidation of crystal form diversity of the HIV protease inhibitor ritonavir by high-throughput crystallization. Proc Natl Acad Sci 100:2180-2184.
9. Anderton C. 2004. The role of Raman microscopy in polymorph screening. Am Pharm Rev 7:42.
10. Zhou G, Wang J, Ge Z, Sun Y. 2002. Ensuring robust polymorph isolation using in-situ Raman spectroscopy. Amer Pharm Rev 5:74-80.
11. Wang F, Wachter JA, Antosz FJ, Berglund KA. 2000. An investigation of solvent-mediated polymorphic transformation of progesterone using insitu Raman spectroscopy. Org Process Res Dev 4:391-395.
12. Anquetil PA, Brenan CJH, Marcolli C, Hunter IW. 2003. Laser Raman spectroscopic analysis of polymorphic forms in microliter fluid volumes. J Pharm Sci 92:149-160.
13. Simmons DL, Ranz RJ, Gyanchandani ND. 1973. Polymorphism in pharmaceuticals III chlorpropamide. Can J Pharm 8:125-127.
14. Perlovich GL, Hansen LK, Bauer-Brandl A. 2001. Interrelation between thermochemical and structural data of polymorphs exemplified by diflunisal. J Pharm Sci 91:1036-1045.
15. Matsuda Y, Tatsumi E. 1990. Physicochemical characterization of furosemide modifications. Int J Pharm 60:11-26.
16. Ghan GA, Lalla JK. 1992. Effect of compressional forces on piroxicam polymorphs. J Pharm Pharmacol 44:678-681.
17. Bland JM, Altman DG. 1995. Multiple significance tests: The Bonferroni method. Br Med J 310:170.